HC Wainwright & Co. Maintains Buy on Alpine Immune Sciences, Raises Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis has reaffirmed a Buy rating on Alpine Immune Sciences (NASDAQ:ALPN) and increased the price target from $17 to $32. This adjustment reflects a more optimistic outlook on the company's stock performance.
December 22, 2023 | 11:10 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst has maintained a Buy rating on Alpine Immune Sciences and raised the price target from $17 to $32, indicating a positive outlook on the stock.
The increase in price target by a reputable analyst typically signals a strong conviction in the company's future performance and can lead to increased investor confidence. This positive sentiment is likely to drive short-term price appreciation as the market reacts to the new price target.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100